U.S. patent application number 10/766403 was filed with the patent office on 2005-01-27 for myocardial perfusion imaging methods and compositions.
This patent application is currently assigned to CV Therapeutics, Inc.. Invention is credited to Belardinelli, Luiz, Rosner, Mitchell.
Application Number | 20050020915 10/766403 |
Document ID | / |
Family ID | 46301810 |
Filed Date | 2005-01-27 |
United States Patent
Application |
20050020915 |
Kind Code |
A1 |
Belardinelli, Luiz ; et
al. |
January 27, 2005 |
Myocardial perfusion imaging methods and compositions
Abstract
A myocardial imaging method that is accomplished by
administering one or more adenosine A.sub.2A adenosine receptor
agonist to a human undergoing myocardial imaging as well as
pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent.
Inventors: |
Belardinelli, Luiz; (Menlo
Park, CA) ; Rosner, Mitchell; (Mountain View,
CA) |
Correspondence
Address: |
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO
IL
60606
US
|
Assignee: |
CV Therapeutics, Inc.
|
Family ID: |
46301810 |
Appl. No.: |
10/766403 |
Filed: |
January 27, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10766403 |
Jan 27, 2004 |
|
|
|
10629386 |
Jul 29, 2003 |
|
|
|
60459803 |
Apr 2, 2003 |
|
|
|
60426902 |
Nov 15, 2002 |
|
|
|
60399177 |
Jul 29, 2002 |
|
|
|
60399176 |
Jul 29, 2002 |
|
|
|
Current U.S.
Class: |
600/431 ;
514/46 |
Current CPC
Class: |
A61K 31/7076 20130101;
A61K 31/7076 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
600/431 ;
514/046 |
International
Class: |
A61B 006/00; A61K
031/70 |
Claims
What is claimed is:
1. A pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent.
2. The pharmaceutical composition of claim 1 wherein the A.sub.2a
receptor agonist is selected from the group consisting of CVT-3033,
CVT-3146, and combinations thereof.
3. The pharmaceutical composition of claim 1 wherein the liquid
carrier comprises water, distilled water, de-ionized water, saline,
a buffer, or combinations thereof.
4. The pharmaceutical composition of claim 1 wherein the co-solvent
comprises methylboronic acid, borate buffer, propylene glycol, or
polyethylene glycol.
5. The pharmaceutical composition of claim 4 wherein the co-solvent
is methylboronic acid.
6. The pharmaceutical composition of claim 5 wherein the A.sub.2a
receptor agonist is CVT-3146.
7. The pharmaceutical composition of claim 6 wherein the CVT-3146
is present in an amount ranging from about 50 micrograms/ml to
about 250 micrograms/ml and the methylboronic acid is present in an
amount from about 0.4% to about 0.6% (w:v).
8. The pharmaceutical composition of claim 7 wherein the liquid
carrier is at least one buffer.
9. The pharmaceutical composition of claim 8 wherein the pH of the
said composition is from about 8.5 to about 10.
10. The pharmaceutical composition of claim 9 wherein the pH is
from about 9.1 to about 9.4.
11. The pharmaceutical composition of claim 3 wherein the
co-solvent is a borate buffer.
12. The pharmaceutical composition of claim 6 wherein the
co-solvent is about 0.5% (w:v) methylboronic acid.
13. The pharmaceutical composition of claim 12 wherein said
composition also comprises a buffer to bring the pH of the
composition to about 9.3.
14. The pharmaceutical composition of claim 13 wherein the CVT-3146
in said composition is present in an amount from about 50 to about
150 micrograms/ml.
15. The pharmaceutical composition of claim 14 wherein the said
composition also comprises about 0.55% (w:v) sodium chloride and
about 50 mM sodium bicarbonate.
16. The pharmaceutical composition of claim 4 wherein the
co-solvent is propylene glycol and the propylene glycol is present
in an amount from about 5% to about 25% (w:v).
17. The pharmaceutical composition of claim 16 wherein the
propylene glycol is present in an amount from about 8% to about 20%
(w:v).
18. The pharmaceutical composition of claim 17 wherein the liquid
carrier includes a buffer to bring said composition to a pH of from
about 6 to about 8.
19. The pharmaceutical composition of claim 18 wherein the said
composition further comprises EDTA.
20. The pharmaceutical composition of claim 16 wherein the A.sub.2a
receptor agonist is CVT-3146 and said CVT-3146 is present in an
amount from about 50 to about 150 micrograms.
21. A method of producing coronary vasodilation without peripheral
vasodilation comprising administering to a human the pharmaceutical
composition of claims 1 or 5 or 16 wherein said composition
contains about 10 to about 600 micrograms of at least one A.sub.2a
receptor agonist.
22. The method of claim 21 wherein the A.sub.2a receptor agonist is
CVT-3146.
23. The method of claim 22 wherein said pharmaceutical composition
is administered by iv bolus.
24. The method of claim 23 wherein said pharmaceutical composition
is administered in about 10 to about 20 seconds.
25. A method of myocardial perfusion imaging of a human comprising
administering a radionuclide and the composition of claims 1 or 5
or 16 either simultaneously or sequentially to a human wherein the
myocardium is examined for areas of insufficient blood flow
following administration of the radionuclide and the
composition.
26. The method of claim 25 wherein the myocardium examination
begins within about 1 minute after the radionuclide and the
composition are administered.
27. The method of claim 26 wherein the A.sub.2a receptor agonist in
said composition causes at least a 2.5 fold increase in coronary
blood flow, such increase in blood flow being achieved for less
than about 5 minutes.
28. The method of claim 25 wherein the A.sub.2a receptor agonist in
said composition is CVT-3146, which CVT-3146 is administered in an
amount of from about 10 to about 600 micrograms in a single iv
bolus.
29. The method of claim 28 wherein the CVT-3146 amount is from
about 100 to about 500 micrograms.
30. The method of claim 28 wherein the CVT-3146 amount is about 400
micrograms.
31. The method of claim 28 wherein said composition is administered
in about 10 to about 30 seconds or less.
32. A method of producing coronary vasodilation without peripheral
vasodilation comprising administering at least 10 .mu.g of at least
one A.sub.2A receptor agonist to a human.
33. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount that does not exceed about 1000
.mu.g.
34. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 10 to about 600
.mu.g.
35. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in a single dose.
36. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered by iv bolus.
37. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 0.05 to about 60
.mu.g/kg and wherein the A.sub.2A receptor agonist is administered
by iv bolus.
38. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 0.1 to about 30
.mu.g/kg wherein the A.sub.2A receptor agonist is administered by
iv bolus.
39. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount no greater than about 20 .mu.g/kg to a
supine patient and wherein the A.sub.2A receptor agonist is
administered by iv bolus.
40. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount no greater than about 10 .mu.g/kg to a
standing patient wherein the A.sub.2A receptor agonist is
administered by iv bolus.
41. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 10 to about 600 .mu.g
wherein the wherein the A.sub.2A receptor agonist is administered
in about 20 seconds.
42. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 10 to about 600 .mu.g
wherein the A.sub.2A receptor agonist is administered in less than
about 10 seconds.
43. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount greater than about 100 .mu.g.
44. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount no greater than 600.mu..
45. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount no greater than 500 .mu.g.
46. The method of claim 32 wherein the A.sub.2A receptor agonist is
administered in an amount ranging from about 100 .mu.g to about 500
.mu.g.
47. The method of claim 32 wherein the A.sub.2A receptor agonist is
selected from the group consisting of CVT-3033, CVT-3146 and
combinations thereof.
48. A method of myocardial perfusion imaging of a human, comprising
administering a radionuclide and a A.sub.2A receptor agonist to the
human wherein the myocardium is examined for areas of insufficient
blood flow following administration of the radionuclide and the
A.sub.2A receptor agonist.
49. The method of claim 48 wherein the myocardium examination
begins within about 1 minute from the time the A.sub.2A receptor
agonist is administered.
50. The method of claim 48 wherein the administration of the
A.sub.2A receptor agonist causes at least a 2.5 fold increase in
coronary blood flow.
51. The method of claim 48 wherein the administration of the
A.sub.2A receptor agonist causes at least a 2.5 fold increase in
coronary blood flow that is achieved within about 1 minute from the
administration of the A.sub.2A receptor agonist.
52. The method of claim 48 wherein the radionuclide and the
A.sub.2A receptor agonist are administered separately.
53. The method of claim 48 wherein the radionuclide and the
A.sub.2A receptor agonist are administered simultaneously.
54. The method of claim 48 wherein the administration of the
A.sub.2A receptor agonist causes at least a 2.5 fold increase in
coronary blood flow for less than about 5 minutes.
55. The method of claim 48 wherein the administration of the
A.sub.2A receptor agonist causes at least a 2.5 fold increase in
coronary blood flow for less than about 3 minutes.
56. The method of claim 48 wherein the A.sub.2A receptor agonist is
CVT-3146 which is administered in an amount ranging from about 10
to about 600 .mu.g in a single iv bolus.
57. The method of claim 56 wherein CVT-3146 is administered in an
amount ranging from about 100 to about 500 .mu.g in a single iv
bolus.
58. The method of claim 48 wherein the a A.sub.2A receptor agonist
is CVT-3146 which is administered in a single dose in an amount
ranging from 10 to about 600 .mu.g that is independent of the
weight of the human being dosed.
59. The method of claim 48 wherein the dose is administered in
about 30 seconds or less.
60. The method of claim 48 wherein the dose is administered in
about 20 seconds or less.
61. The method of claim 48 wherein the A.sub.2A receptor agonist is
administered in a single dose.
Description
[0001] This application is a continuation-in-part of U.S. patent
application Ser. No. 10/629,386 filed on Jul. 29, 2003, which in
turn claims the benefit of the filing dates of application Ser.
Nos. 60/459,803 filed on Apr. 29, 2003, and 60/462,902 filed on
Nov. 15, 2002, and 60/399,177 filed on Jul. 29, 2002, and
60/399,176 filed on Jul. 29, 2002. The specifications of each of
these applications are incorporated in their entirety herein by
reference.
BACKGROUND OF THE INVENTION
[0002] (1) Field of the Invention
[0003] This invention relates to myocardial imaging methods that
are accomplished by administering doses of one or more adenosine
A.sub.2A adenosine receptor agonists to a mammal undergoing
myocardial imaging. This invention also relates to pharmaceutical
compositions useful in myocardial imaging methods.
[0004] (2) Description of the Art
[0005] Myocardial perfusion imaging (MPI) is a diagnostic technique
useful for the detection and characterization of coronary artery
disease. Perfusion imaging uses materials such as radionuclucides
to identify areas of insufficient blood flow. In MPI, blood flow is
measured at rest, and the result compared with the blood flow
measured during exercise on a treadmill (cardiac stress testing),
such exertion being necessary to stimulate blood flow.
Unfortunately, many patients are unable to exercise at levels
necessary to provide sufficient blood flow, due to medical
conditions such as peripheral vascular disease, arthritis, and the
like.
[0006] Therefore, a pharmacological agent that increases cardiac
blood flow (CBF) for a short period of time would be of great
benefit, particularly one that did not cause peripheral
vasodilation. Vasodilators, for example dipyridamole, have been
used for this purpose in patients prior to imaging with
radionuclide. Dipyridamole is an effective vasodilator, but side
effects such as pain and nausea limit the usefulness of treatment
with this compound.
[0007] Adenosine, a naturally occurring nucleoside, also is useful
as a vasodilator. Adenosine exerts its biological effects by
interacting with a family of adenosine receptors characterized as
subtypes A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3 Adenoscan.RTM.
(Fujisawa Healthcare Inc.) is a formulation of a naturally
occurring adenosine. Adenoscan.RTM. has been marketed as an
adjuvant in perfusion studies using radioactive thallium-201.
However, its use is limited due to side effects such as flushing,
chest discomfort, the urge to breathe deeply, headache, throat,
neck, and jaw pain. These adverse effects of adenosine are due to
the activation of other adenosine receptor subtypes other than
A.sub.2A, which mediates the vasodilatory effects of adenosine.
Additionally, the short half-life of adenosine necessitates
multiple treatments during the procedure, further limiting its use.
Adenoscan.RTM. is contraindicated in many patients including those
with second- or third-degree block, sinus node disease,
bronchoconstrictive or bronchospastic lung disease, and in patients
with known hypersensitivity to the drug.
[0008] Other potent and selective agonists for the A.sub.2A
adenosine receptor are known. For example, MRE-0470 (Medco) is an
adenosine A.sub.2A receptor agonist that is a potent and selective
derivative of adenosine. WRC-0470 (Medco) is an adenosine A.sub.2A
agonist used as an adjuvant in imaging. In general, compounds such
as these have a high affinity for the A.sub.2A receptor, and
consequently, a long duration of action, which is undesirable in
imaging.
[0009] Thus, there is still a need for a method of producing rapid
and maximal coronary vasodilation in mammals without causing
corresponding peripheral vasodilation, which would be useful for
myocardial imaging with radionuclide agents. Preferred compounds
would be selective for the A.sub.2A adenosine receptor and have a
short duration of action (although longer acting than compounds
such as adenosine), thus obviating the need for multiple
dosing.
SUMMARY OF THE INVENTION
[0010] The following are several aspects of this invention.
[0011] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering at
least 10 .mu.g of at least one A.sub.2A receptor agonist to the
human.
[0012] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering no
more than about 1000 .mu.g of a A.sub.2A receptor agonist to the
human.
[0013] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering a
A.sub.2A receptor agonist in an amount ranging from about 10 to
about 600 .mu.g to the human.
[0014] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering about
300 .mu.g of a A.sub.2A receptor agonist to the human.
[0015] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering about
400 .mu.g of a A.sub.2A receptor agonist to the human.
[0016] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering about
500 .mu.g of a A.sub.2A receptor agonist to the human.
[0017] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering about
600 .mu.g of a A.sub.2A receptor agonist to the human.
[0018] A method of producing coronary vasodilation without
peripheral vasodilation in a human, comprising administering about
700 .mu.g of a A.sub.2A receptor agonist to the human.
[0019] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 10 to about 600 .mu.g and wherein the
A.sub.2A receptor agonist is administered in a single dose.
[0020] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein about 300 .mu.g of the A.sub.2A receptor agonist is
administered in a single dose.
[0021] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein about 400 .mu.g of the A.sub.2A receptor agonist is
administered in a single dose.
[0022] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein about 500 .mu.g of the A.sub.2A receptor agonist is
administered in a single dose.
[0023] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein about 600 .mu.g of the A.sub.2A receptor agonist is
administered in a single dose.
[0024] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein about 700 .mu.g of the A.sub.2A receptor agonist is
administered in a single dose.
[0025] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 10 to about 600 .mu.g and wherein the
A.sub.2A receptor agonist is administered by iv bolus.
[0026] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 0.05 to about 60 .mu.g/kg and wherein the
A.sub.2A receptor agonist is administered by iv bolus.
[0027] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 0.1 to about 30 .mu.g/kg wherein the
A.sub.2A receptor agonist is administered by iv bolus.
[0028] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount no greater than about 20 .mu.g/kg to a supine patient
wherein the A.sub.2A receptor agonist is administered by iv
bolus.
[0029] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount no greater than about 10 .mu.g/kg to a standing patient
wherein the A.sub.2A receptor agonist is administered by iv
bolus.
[0030] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 10 to about 600 .mu.g wherein the wherein
the A.sub.2A receptor agonist is administered in about 20
seconds.
[0031] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist in an amount ranging from about 10 to about 600 .mu.g
wherein the A.sub.2A receptor agonist is administered in less than
about 10 seconds.
[0032] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount greater than about 10 .mu.g.
[0033] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount greater than about 100 .mu.g.
[0034] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount no greater than 600.mu..
[0035] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount no greater than 500 .mu.g.
[0036] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is administered in an
amount ranging from about 100 .mu.g to about 500 .mu.g and
preferably about 400 .mu.g.
[0037] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the A.sub.2A receptor agonist is selected from the
group consisting of CVT-3033, CVT-3146 and combinations
thereof.
[0038] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and about 300 .mu.g of a
compound selected from the group consisting of CVT-3033, CVT-3146
to the human.
[0039] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and about 400 .mu.g of a
compound selected from the group consisting of CVT-3033, CVT-3146
to the human.
[0040] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and about 500 .mu.g of a
compound selected from the group consisting of CVT-3033, CVT-3146
to the human.
[0041] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and about 600 .mu.g of a
compound selected from the group consisting of CVT-3033, CVT-3146
to the human.
[0042] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and about 700 .mu.g of a
compound selected from the group consisting of CVT-3033, CVT-3146
to the human.
[0043] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the myocardium is examined for areas of
insufficient blood flow following administration of the
radionuclide and the A.sub.2A receptor agonist.
[0044] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the myocardium is examined for areas of
insufficient blood flow following administration of the
radionuclide and the A.sub.2A receptor agonist wherein the
myocardium examination begins within about 1 minute from the time
the A.sub.2A receptor agonist is administered.
[0045] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the administration of the A.sub.2A receptor agonist
causes at least a 2.5 fold increase in coronary blood flow.
[0046] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the administration of the A.sub.2A receptor agonist
causes at least a 2.5 fold increase in coronary blood flow that is
achieved within about 1 minute from the administration of the
A.sub.2A receptor agonist.
[0047] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the radionuclide and the A.sub.2A receptor agonist
are administered separately.
[0048] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and an A.sub.2A receptor
agonist wherein the radionuclide and the A.sub.2A receptor agonist
are administered simultaneously.
[0049] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the administration of the A.sub.2A receptor agonist
causes at least a 2.5 fold increase in coronary blood flow for less
than about 5 minutes.
[0050] A method of myocardial perfusion imaging of a human,
comprising administering a radionuclide and a A.sub.2A receptor
agonist wherein the administration of the A.sub.2A receptor agonist
causes at least a 2.5 fold increase in coronary blood flow for less
than about 3 minutes.
[0051] A method of myocardial perfusion imaging of a human,
comprising administering CVT-3146 in an amount ranging from about
10 to about 600 .mu.g in a single iv bolus.
[0052] A method of myocardial perfusion imaging of a human,
comprising administering CVT-3146 in an amount ranging from about
100 to about 500 .mu.g and more preferably about 400 .mu.g in a
single iv bolus.
[0053] A method of myocardial perfusion imaging of a human
comprising administering CVT-3146 by iv bolus in an amount ranging
from 10 to about 600 .mu.g that is independent of the weight of the
human being dosed.
[0054] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent.
[0055] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the A.sub.2a receptor agonist is selected from
the group consisting of CVT-3033, CVT-3146, and combinations
thereof.
[0056] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the liquid carrier comprises water, distilled
water, de-ionized water, saline, a buffer, or combinations
thereof.
[0057] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent comprises methylboronic acid,
borate buffer, propylene glycol, or polyethylene glycol.
[0058] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is methylboronic acid.
[0059] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is methylboronic acid and wherein
the A.sub.2a receptor agonist is CVT-3146.
[0060] Pharmaceutical compositions comprising CVT-3146, at least
one liquid carrier, and at least one co-solvent wherein the
co-solvent is methylboronic acid wherein the CVT-3146 is present in
an amount ranging from about 50 micrograms/ml to about 250
micrograms/ml and the methylboronic acid is present in an amount
from about 0.4% to about 0.6% (w:v).
[0061] Pharmaceutical compositions comprising CVT-3146, at least
one liquid carrier, and at least one co-solvent wherein the
co-solvent is methylboronic acid having a pH of from about 9.1 to
about 9.4.
[0062] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is a borate buffer and preferably
about 0.5% (w:v) methylboronic acid.
[0063] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein a co-solvent is a borate buffer and preferably
about 0.5% (w:v) methylboronic acid and wherein the composition
further comprises a buffer to bring the pH of the composition to
about 9.3.
[0064] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is a borate buffer and wherein
the A.sub.2A receptor agonist is CVT-3146 which is preferably
present in the composition in an amount from about 50 to about 150
micrograms/ml.
[0065] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is a borate buffer, wherein the
A.sub.2A receptor agonist is CVT-3146 which is preferably present
in the composition in an amount from about 50 to about 150
micrograms/ml and wherein said composition also comprises about
0.55% (w:v) sodium chloride and about 50 mM sodium bicarbonate.
[0066] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is propylene glycol and the
propylene glycol is present in an amount of from about 5% to about
25% (w:v) and preferably in an amount of from about 8% to about 20%
(w:v).
[0067] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is propylene glycol and the
propylene glycol is present in an amount of from about 5% to about
25% (w:v) wherein the liquid carrier includes a buffer to bring
said composition to a pH of from about 6 to about 8.
[0068] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is propylene glycol and the
propylene glycol is present in an amount of from about 5% to about
25% wherein said composition further comprises EDTA.
[0069] Pharmaceutical compositions comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the co-solvent is propylene glycol and the
propylene glycol is present in an amount of from about 5% to about
25% (w:v) and preferably in an amount of from about 8% to about 20%
(w:v) wherein the A.sub.2a receptor agonist is CVT-3146 and said
CVT-3146 is present in an amount from about 50 to about 150
micrograms.
[0070] A method of producing coronary vasodilation without
peripheral vasodilation comprising administering to a human the
pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent.
[0071] A method of producing coronary vasodilation without
peripheral vasodilation comprising administering to a human the
pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the A.sub.2a receptor agonist is CVT-3146.
[0072] A method of producing coronary vasodilation without
peripheral vasodilation comprising administering to a human the
pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the A.sub.2a receptor agonist is CVT-3146 and
wherein said pharmaceutical composition is administered by iv
bolus.
[0073] A method of producing coronary vasodilation without
peripheral vasodilation comprising administering to a human the
pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the A.sub.2a receptor agonist is CVT-3146 and
wherein said pharmaceutical composition is administered by iv bolus
and wherein said pharmaceutical composition is administered in
about 10 to about 20 seconds.
[0074] A method of producing coronary vasodilation without
peripheral vasodilation comprising administering to a human the
pharmaceutical composition comprising at least one A.sub.2a
receptor agonist, at least one liquid carrier, and at least one
co-solvent wherein the A.sub.2a receptor agonist is CVT-3146
wherein the total amount of CVT-3146 that is administered ranges
from about 100 to about 500 micrograms and is more preferably about
400 micrograms.
[0075] In all of the methods above, the dose is preferably
administered in a single dose.
[0076] In all of the methods above, at least one radionuclide is
administered before, with or after the administration of the
A.sub.2A receptor agonist to facilitate myocardial imaging.
[0077] In all of the methods above, the dose is preferably
administered in 60 seconds or less, preferably 30 seconds or less,
and more preferably 20 seconds or less.
DESCRIPTION OF THE FIGURES
[0078] FIG. 1 are intracoronary Doppler flow profiles following
administration of 18 .mu.g adenosine IC bolus (top) and 30 .mu.g
CVT-3146 IV bolus;
[0079] FIG. 2 is a plot showing the relationship of the dose of
CVT-3146 on coronary peak flow rates;
[0080] FIG. 3 is a Table that reports the duration of time the
coronary flow velocity is greater than or equal to 2.5 times
baseline coronary flow velocity for varying doses of CVT-3146
wherein "n" refers to the number of human patients dosed;
[0081] FIG. 4 is a plot of the time course of the average peak
velocity (APV) ratio for human patients receiving 400 .mu.g of
CVT-3146 IV bolus;
[0082] FIG. 5 is a plot of the time course of heart rate for human
patients receiving 400 .mu.g of CVT-3146 IV bolus;
[0083] FIG. 6 is the time course of blood pressure for human
patients receiving 400 .mu.g of CVT-3146 IV bolus; and
[0084] FIG. 7 is an adverse event Table.
[0085] FIG. 8 is a plot of the change over time of mean CVT-3146
plasma concentration in healthy male volunteers in a supine
position. The various curves relate to different amounts of
CVT-3146 administered to the patients;
[0086] FIGS. 9 and 10 are plots of the mean change in heart rate of
healthy male volunteers either in a standing position or in a
supine position over time for various bolus dosing levels of
CVT-3146;
[0087] FIG. 11 is a plot of the maximum change in heart rate in
relationship to the total dose of CVT-3146 administered to standing
or supine human male patients. In the plot, the term "DBS" refers
to the observed data point while "fit" refers to a curve fitted to
the observed data points;
[0088] FIG. 12 is a plot of heart rate--(area under curve) AUC(0-15
min) of change from baseline in relationship to the total dose of
CVT-3146 administered to standing or supine human subjects;
[0089] FIG. 13 is a plot of the maximum change from baseline heart
rate at maximum plasma concentration of CVT-3146 for patients in a
supine position;
[0090] FIG. 14 is a plot of heart rate--(area under the curve--time
v. effect) AUCE (0-15 min) of change from baseline versus plasma
AUC(0-15 min) for patients in a supine position;
[0091] FIG. 15 is a plot of the time profiles of mean heart rate
change from a baseline versus mean plasma concentration over time
for a 20 .mu.g/kg dose of CVT-3146;
[0092] FIG. 16 is a plot of the average peak to blood flow velocity
over time following administration of CVT-3146 measured at the
pulmonary artery (PA), the four limb artery (FA), brain arterial
vasculature (BA) and in the left circumflex coronary artery
(LCS);
[0093] FIG. 17 is a plot of the percent change in heart rate (HR)
and blood pressure (BP) for various doses of CVC-3146; and
[0094] FIG. 18 is a plot of the change in LBF and RBF blood flow
upon administering increasing amounts of ADO or CVT-3146 to awake
dogs.
DESCRIPTION OF THE INVENTION
[0095] Potent A.sub.2A agonists are useful as adjuncts in cardiac
imaging when added either prior to dosing with an imaging agent or
simultaneously with an imaging agent. Suitable imaging agents
include .sup.201Thallium or .sup.99mTechnetium-Sestamibi,
.sup.99mTcteboroxime, and .sup.99mTc(III).
[0096] New and potent A.sub.2A agonists that increase CBF but do
not significantly increase peripheral blood flow have been
identified. The A.sub.2A agonists, and especially CVT-3146 and
CVT-3033 have a rapid onset and a short duration when administered.
An unexpected and newly identified benefit of these new compounds
is that they are very useful when administered in a very small
quantity in a single bolus intravenous (i.v.) injection. The
A.sub.2A receptor agonists can be administered in amounts as little
as 10 .mu.g and as high as 600 .mu.g or more and still be effective
with few if any side-effects. An optimal dose may include as little
as 10 .mu.g and as much as about 1000 .mu.g or more of a A.sub.2A
receptor agonist. More preferably, an optimal dose will range from
about 100 to about 500 .mu.g of at least one A.sub.2A receptor
agonist. It is preferred that the A.sub.2A receptor agonist is
administered in a single bolus injection in an amount selected from
about 300 .mu.g, about 400 .mu.g, about 500 .mu.g, about 600 .mu.g,
and about 700 .mu.g. These amounts are unexpectedly small when
compared with adenosine which is typically administered
continuously by IV infusion at a rate of about 140 .mu.g/kg/min.
Unlike adenosine, the same dosage of A.sub.2A receptor agonists,
and in particular, CVT-3146 and CVT-3033 can be administered to a
human patient regardless of the patient's weight. Thus, the
administration of a single uniform amount of a A.sub.2A receptor
agonists by iv bolus for myocardial imaging is dramatically simpler
and less error prone than the time and weight dependent
administration of adenosine. The dose of A.sub.2A receptor agonist
administered to a human patient can, however, be determined by
weight. Typically, a weight based dose will range from about 0.05
to about 60 .mu.g/kg and more preferably from about 0.1 to about 30
.mu.g/kg. CVT-3146 in particular is generally well tolerated when
administered in an amount up to 10 .mu.g/kg in standing patients
and up to 20 .mu.g/kg in supine patients.
[0097] A.sub.2A agonists of this invention may be administered
orally, intravenously, through the epidermis or by any other means
known in the art for administering therapeutic agents with bolus
i.v. administration being preferred. In one embodiment, the bolus
dosing occurs in 60 seconds or less. In yet other embodiments, the
bolus dosing occurs in about 30 seconds or less, and more
preferably in about 20 seconds or less or in about 10 seconds or
less.
[0098] The A.sub.2A agonists of this invention are preferably
administered in a single dose. The term "single dose" refers
generally to a single quickly administered dose of a therapeutic
amount of at least one A.sub.2A receptor agonist. The term "single
dose" does not encompass a dose or doses administered over an
extended period of time by, for example continuous i.v.
infusion.
[0099] One aspect of this invention is directed to pharmaceutical
compositions. The term "pharmaceutical composition" refers to the
combination of one or more A.sub.2A agonist compounds of this
invention with at least one liquid carrier that together form a
solution or a suspension. Lyophilized powders including
compositions of this invention fall within the scope of
"pharmaceutical compositions" so long as the powders are intended
to be reconstituted by the addition of a suitable liquid carrier
prior to use. Examples of suitable liquid carriers include, but are
not limited to water, distilled water, de-ionized water, saline,
buffer solutions, normal isotonic saline solution, dextrose in
water, and combinations thereof. Such pharmaceutical compositions
are generally suitable for injection.
[0100] The term "buffer solution" or "buffer" as used herein refers
to a solution containing both a weak acid and its conjugate weak
base. The buffer solutions are used in pharmaceutical compositions
of this invention in order to resist pH changes. Non-limiting
examples of useful buffer solutions are solutions that comprise
sodium bicarbonate and sodium phosphate.
[0101] A.sub.2A receptor agonists of this invention are prepared
and then administered, with or without intervening storage, as a
pharmaceutical composition. Various properties considered when
formulating pharmaceutical compositions of this invention include,
but are not limited to product shelf life, A.sub.2A receptor
agonist solubility, composition pH, vein irritation, hemolysis,
storage conditions (e.g., whether the pharmaceutical composition
will be stored at room temperature or some other temperature) and
the ability to withstand sterilization procedures.
[0102] One method to achieve the desired pharmaceutical composition
properties is to include a co-solvent in the pharmaceutical
composition. The co-solvent can be selected from any liquid or
compound in solution that imparts the desired properties to the
pharmaceutical composition. Examples of useful co-solvents include,
but are not limited to methylboronic acid, borate buffer, propylene
glycol, or polyethylene glycol. The amount of co-solvent in the
pharmaceutical composition will depend upon properties, such as
solubility and stability of the chosen A.sub.2A receptor
agonist.
[0103] A preferred A.sub.2A receptor agonist of this invention is
CVT-3146. CVT-3146 has solubility in water of about 50
micrograms/mL. Therefore, CVT-3146 can be dissolved and
administered in water so long as the desired weight amount of
CVT-3146 can be administered in an acceptable volume. For example,
a preferred dose of about 400 micrograms can be administered in 8
mL of water. If this volume is too great for administration
purposes, or if the pharmaceutical composition will be stored at
other than room temperature (RT), then additional ingredients can
be added to the composition to increase the solubility of CVT-3146
in the composition and/or to provide the resulting pharmaceutical
composition with other improved properties such as improved
stability and storage properties. Pharmaceutical compositions of
this invention that include CVT-3146 may include up to about 1
milligram/mL of CVT-3146. It is preferred that pharmaceutical
compositions including CVT-3146 include from about 50 to about 250
micrograms/mL, and more preferably from about 50 to 150
micrograms/mL of CVT-3146.
[0104] In order to improve their solubility and storage properties,
A.sub.2A receptor agonists of this invention can be administered in
a pharmaceutical composition including a methylboronic acid (MBA)
co-solvent. The methylboronic acid is added to the pharmaceutical
composition to improve agonist solubility and shelf life. MBA
increases the pH of the resulting composition. The solubility of
CVT-3146 in a pharmaceutical composition including MBA tends to
decrease as the composition pH drops towards neutral. Therefore,
with CVT-3146, an optimal MBA-containing composition pH is from
about 8.5 to 10 with a pH of about 9.1 to about 9.4 being preferred
and a pH of about 9.3 being most preferred. This corresponds to a
composition including from about 50 to about 250 mg/mL of MBA. As
an alternative to MBA, CVT-3146 can be combined with a borate
buffer solution. Typically, a borate buffer solution will be
comprised of an aqueous solution of sodium borate that is adjusted
to the desired pH such as a pH of 9.3 using an acid or a base.
[0105] MBA containing pharmaceutical compositions can suffer from
storage problems. Namely, MBA can cause delamination when packaged
in certain type I glass vessels. This problem can be overcome by
storing the MBA containing pharmaceutical compositions in plastic
vessels or in more resistant type I glass vessels.
[0106] If A.sub.2A receptor agonist containing pharmaceutical
compositions having a pH closer to neutral are desired, then an
alternative is to combine A.sub.2A receptor agonists with a
propylene glycol (PG) co-solvent. The amount of PG used in the
composition may range from about 5% to up to 25% by volume with a
range of about 8% to about 20% by volume being more preferred when
using CVT-3146. An alternative to PG is polyethylene glycol--PEG. A
preferred PEG will have an average molecular weight of from about
200 to 400.
[0107] Preferably, the CVT-3146 composition including PG or PEG
will have a pH of from about 6 to about 8 with a pH of about 7
being preferred. Any physiologically acceptable buffer capable of
adjusting the composition pH to the desired value can be used.
Additional optional ingredients such as EDTA and dimethylacetamide
could be employed in the composition as well.
[0108] The pharmaceutical compositions of this invention may
include one or more anti-oxidants such as butylated hydroxyanisole
(BHA).
[0109] A first class of compounds that are potent and selective
agonists for the A.sub.2A adenosine receptor that are useful in the
methods of this invention are 2-adenosine N-pyrazole compounds
having the formula: 1
[0110] wherein R.sup.1.dbd.CH.sub.2OH, --CONR.sub.5R.sub.6;
[0111] R.sup.3 is independently selected from the group consisting
of C.sub.1-15 alkyl, halo, NO.sub.2, CF.sub.3, CN, OR.sup.20,
SR.sup.20, N(R.sup.20).sub.2, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, SO.sub.2NR.sup.20COR.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and
OCON(R.sup.20).sub.2, --CONR.sup.7R.sup.8, C.sub.2-15 alkenyl,
C.sub.2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the
alkyl, alkenyl, alkynyl, aryl, heterocyclyl and heteroaryl
substituents are optionally substituted with from 1 to 3
substituents independently selected from the group consisting of
halo, alkyl, NO.sub.2, heterocyclyl, aryl, heteroaryl, CF.sub.3,
CN, OR.sup.20, SR.sup.20, N(R.sup.20).sub.2, S(O)R.sup.22,
SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
SO.sub.2NR.sup.20COR.sup.22, SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
and wherein the optional substituted heteroaryl, aryl, and
heterocyclyl substituents are optionally substituted with halo,
NO.sub.2, alkyl, CF.sub.3, amino, mono- or di-alkylamino, alkyl or
aryl or heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, or OR.sup.20;
[0112] R.sup.5 and R.sup.6 are each individually selected from H,
and C.sub.1-C.sub.15 alkyl that is optionally substituted with from
1 to 2 substituents independently selected from the group of halo,
NO.sub.2, heterocyclyl, aryl, heteroaryl, CF.sub.3, CN, OR.sup.20,
SR.sup.20, N(R.sup.20).sub.2, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, SO.sub.2NR.sup.20COR.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
wherein each optional substituted heteroaryl, aryl, and
heterocyclyl substituent is optionally substituted with halo,
NO.sub.2, alkyl, CF.sub.3, amino, monoalkylamino, dialkylamino,
alkylamide, arylamide, heteroarylamide, NCOR.sup.22,
NR.sup.20SO.sub.2R.sup.22, COR.sup.20, CO.sub.2R.sup.20,
CON(R.sup.20).sub.2, NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, and OR.sup.20;
[0113] R.sup.7 is selected from the group consisting of hydrogen,
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, aryl, heterocyclyl and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from the group of halo, NO.sub.2, heterocyclyl, aryl,
heteroaryl, CF.sub.3, CN, OR.sup.20, SR.sup.20, N(R.sup.20).sub.2,
S(O)R.sup.22, SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
SO.sub.2NR.sup.20COR.sup.22, SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20 and OCON(R.sup.20).sub.2
and wherein each optional substituted heteroaryl, aryl and
heterocyclyl substituent is optionally substituted with halo,
NO.sub.2, alkyl, CF.sub.3, amino, mono- or di-alkylamino, alkyl or
aryl or heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, and OR.sup.20;
[0114] R.sup.8 is selected from the group consisting of hydrogen,
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from the group consisting of halo, NO.sub.2, heterocyclyl,
aryl, heteroaryl, CF.sub.3, CN, OR.sup.20, SR.sup.20,
N(R.sup.20).sub.2, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, SO.sub.2NR.sup.20COR.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2, N(R.sup.20).sub.2,
NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
and wherein each optional substituted heteroaryl, aryl, and
heterocyclyl substituent is optionally substituted with halo,
NO.sub.2, alkyl, CF.sub.3, amino, mono- or di-alkylamino, alkyl or
aryl or heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, and OR.sup.20;
[0115] R.sup.20 is selected from the group consisting of H,
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, heterocyclyl, aryl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or
heteroaryl amide, CN, O--C.sub.1-6 alkyl, CF.sub.3, aryl, and
heteroaryl;
[0116] R.sup.22 is selected from the group consisting of C.sub.1-15
alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl, heterocyclyl, aryl,
and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl,
aryl, and heteroaryl substituents are optionally substituted with
from 1 to 3 substituents independently selected from halo, alkyl,
mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN,
O--C.sub.1-6 alkyl, CF.sub.3, aryl, and heteroaryl; and wherein
R.sup.2 and R.sup.4 are selected from the group consisting of H,
C.sub.1-6 alkyl and aryl, wherein the alkyl and aryl substituents
are optionally substituted with halo, CN, CF.sub.3, OR.sup.20 and
N(R.sup.20).sub.2 with the proviso that when R.sup.2 is not
hydrogen then R.sup.4 is hydrogen, and when R.sup.4 is not hydrogen
then R.sup.2 is hydrogen.
[0117] In an related group of compounds of this invention, R.sup.3
is selected from the group consisting of C.sub.1-15 alkyl, halo,
CF.sub.3, CN, OR.sup.20, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, COR.sup.20, CO.sub.2R.sup.20,
--CONR.sup.7R.sup.8, aryl and heteroaryl wherein the alkyl, aryl
and heteroaryl substituents are optionally substituted with from 1
to 3 substituents independently selected from the group consisting
of halo, aryl, heteroaryl, CF.sub.3, CN, OR.sup.20, SR.sup.20,
S(O)R.sup.22, SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
COR.sup.20, CO.sub.2R.sup.20 or CON(R.sup.20).sub.2, and each
optional heteroaryl and aryl substituent is optionally substituted
with halo, alkyl, CF.sub.3 CN, and OR.sup.20; R.sup.5 and R.sup.6
are independently selected from the group of H and C.sub.1-C.sub.15
alkyl including one optional aryl substituent and each optional
aryl substituent that is optionally substituted with halo or
CF.sub.3; R.sup.7 is selected from the group consisting of
C.sub.1-15 alkyl, C.sub.2-15 alkynyl, aryl, and heteroaryl, wherein
the alkyl, alkynyl, aryl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from the group consisting of halo, aryl, heteroaryl,
CF.sub.3, CN, OR.sup.20, and each optional heteroaryl and aryl
substituent is optionally substituted with halo, alkyl, CF.sub.3
CN, or OR.sup.20; R.sup.8 is selected from the group consisting of
hydrogen and C.sub.1-15 alkyl; R.sup.20 is selected from the group
consisting of H, C.sub.1-4 alkyl and aryl, wherein alkyl and aryl
substituents are optionally substituted with one alkyl substituent;
and R.sup.22 is selected from the group consisting of C.sub.1-4
alkyl and aryl which are each optionally substituted with from 1 to
3 alkyl group.
[0118] In yet another related class of compounds, R.sup.1 is
CH.sub.2OH; R.sup.3 is selected from the group consisting of
CO.sub.2R.sup.20, --CONR.sup.7R.sup.8 and aryl where the aryl
substituent is optionally substituted with from 1 to 2 substituents
independently selected from the group consisting of halo, C.sub.1-6
alkyl, CF.sub.3 and OR.sup.20; R.sup.7 is selected from the group
consisting of hydrogen, C.sub.1-8 alkyl and aryl, where the alkyl
and aryl substituents are optionally substituted with one
substituent selected from the group consisting of halo, aryl,
CF.sub.3, CN, OR.sup.20 and wherein each optional aryl substituent
is optionally substituted with halo, alkyl, CF.sub.3 CN, and
OR.sup.20; R.sup.8 is selected from the group consisting of
hydrogen and C.sub.1-8 alkyl; and R.sup.20 is selected from
hydrogen and C.sub.1-4 alkyl.
[0119] In a still another related class of compounds of this
invention, R.sup.1.dbd.CH.sub.2OH; R.sup.3 is selected from the
group consisting of CO.sub.2R.sup.20, --CONR.sup.7R.sup.8, and aryl
that is optionally substituted with one substituent selected from
the group consisting of halo, C.sub.1-3 alkyl and OR.sup.20;
R.sup.7 is selected from of hydrogen, and C.sub.1-3 alkyl; R.sup.8
is hydrogen; and R.sup.20 is selected from hydrogen and C.sub.1-4
alkyl. In this preferred embodiment, R.sup.3 is most preferably
selected from --CO.sub.2Et and --CONHEt.
[0120] In yet another related class of compounds, R.sup.1=--CONHEt,
R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20,
--CONR.sup.7R.sup.8, and aryl in that aryl is optionally
substituted with from 1 to 2 substituents independently selected
from the group consisting of halo, C.sub.1-3 alkyl, CF.sub.3 or
OR.sup.20; R.sup.7 is selected from the group consisting of
hydrogen, and C.sub.1-8 alkyl that is optionally substituted with
one substituent selected from the group consisting of halo,
CF.sub.3, CN or OR.sup.20; R.sup.8 is selected from the group
consisting of hydrogen and C.sub.1-3 alkyl; and R.sup.20 is
selected from the group consisting of hydrogen and C.sub.1-4 alkyl.
In this more preferred embodiment, R.sup.8 is preferably hydrogen,
R.sup.7 is preferably selected from the group consisting of
hydrogen, and C.sub.1-3, and R.sup.20 is preferably selected from
the group consisting of hydrogen and C.sub.1-4 alkyl.
[0121] Specific useful compounds are selected from ethyl
1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu-
rin-2-yl} pyrazole-4-carboxylate,
(4S,2R,3R,5R)-2-{6-amino-2-[4-(4-chlorop-
henyl)pyrazolyl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[4-(4-methoxyphenyl)pyrazolyl]purin-9-yl}-5-(h-
ydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[4-(4-methylphen-
yl)pyrazolyl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(1-{9-[(4S,2R,3R,
5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-amino-
purin-2-yl}pyrazol-4-yl)-N-methylcarboxamide,
1-{9-[(4S,2R,3R,5R)-3,4-dihy-
droxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazole-4-carboxyli-
c acid,
(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-
-aminopurin-2-yl}pyrazol-4-yl)-N,N-dimethylcarboxamide,
(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop-
urin-2-yl}pyrazol-4-yl)-N-ethylcarboxamide,
1-{9-[(4S,2R,3R,5R)-3,4-dihydr-
oxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazole-4-carboxamide-
,
1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop-
urin-2-yl}pyrazol-4-yl)-N-(cyclopentylmethyl)carboxamide,
(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop-
urin-2-yl}pyrazol-4-yl)-N-[(4-chlorophenyl)methyl]carboxamide,
Ethyl 2-[(1-{9-[(4S,2R,
3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-am-
inopurin-2-yl}pyrazol-4-yl)carbonylamino]acetate, and mixtures
thereof.
[0122] A second class of compounds that are potent and selective
agonists for the A.sub.2A adenosine receptor that are useful in the
methods of this invention are 2-adenosine C-pyrazole compounds
having the following formula: 2
[0123] wherein
[0124] R.sup.1 is --CH.sub.2OH, and --C(.dbd.O)NR.sup.5R.sup.6;
[0125] R.sup.2 is selected from the group consisting of hydrogen,
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from the group consisting of halo, NO.sub.2, heterocyclyl,
aryl, heteroaryl, CF.sub.3, CN, OR.sup.20, SR.sup.20,
N(R.sup.20).sub.2, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, SO.sub.2NR.sup.20COR.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
and wherein each optional heteroaryl, aryl, and heterocyclyl
substituent is optionally substituted with halo, NO.sub.2, alkyl,
CF.sub.3, amino, mono- or di-alkylamino, alkyl or aryl or
heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, or OR.sup.20;
[0126] R.sup.3, R.sup.4 are individually selected from the group
consisting of hydrogen, C.sub.1-15 alkyl, C.sub.2-15 alkenyl,
C.sub.2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, halo,
NO.sub.2, CF.sub.3, CN, OR.sup.20, SR.sup.20, N(R.sup.20).sub.2,
S(O)R.sup.22, SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
SO.sub.2NR.sup.20COR.sup.22, SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and
heteroaryl substituents are optionally substituted with from 1 to 3
substituents individually selected from the group consisting of
halo, NO.sub.2, heterocyclyl, aryl, heteroaryl, CF.sub.3, CN,
OR.sup.20, SR.sup.20, N(R.sup.20).sub.2, S(O)R.sup.22,
SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
SO.sub.2NR.sup.20COR.sup.22, SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(R.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
and wherein each optional heteroaryl, aryl, and heterocyclyl
substituent is optionally substituted with halo, NO.sub.2, alkyl,
CF.sub.3, amino, mono- or di-alkylamino, alkyl or aryl or
heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, or OR.sup.20;
[0127] R.sup.5 and R.sup.6 are each individually H, C1-15 alkyl
with from 1 to 2 substituents independently selected from the group
consisting of halo, NO.sub.2, heterocyclyl, aryl, heteroaryl,
CF.sub.3, CN, OR.sup.20, SR.sup.20, N(R.sup.20).sub.2,
S(O)R.sup.22, SO.sub.2R.sup.22, SO.sub.2N(R.sup.20).sub.2,
SO.sub.2NR.sup.20COR.sup.22, SO.sub.2NR.sup.20CO.sub.2R.sup.22,
SO.sub.2NR.sup.20CON(R.sup.20).sub.2,
N(R.sup.20).sub.2NR.sup.20COR.sup.22, NR.sup.20CO.sub.2R.sup.22,
NR.sup.20CON(R.sup.20).sub.2, NR.sup.20C(NR.sup.20)NHR.sup.23,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
CONR.sup.20SO.sub.2R.sup.22, NR.sup.20SO.sub.2R.sup.22,
SO.sub.2NR.sup.20CO.sub.2R.sup.22, OCONR.sup.20SO.sub.2R.sup.22,
OC(O)R.sup.20, C(O)OCH.sub.2OC(O)R.sup.20, and OCON(R.sup.20).sub.2
and wherein each optional heteroaryl, aryl, and heterocyclyl
substituent is optionally substituted with halo, NO.sub.2, alkyl,
CF.sub.3, amino, mono- or di-alkylamino, alkyl or aryl or
heteroaryl amide, NCOR.sup.22, NR.sup.20SO.sub.2R.sup.22,
COR.sup.20, CO.sub.2R.sup.20, CON(R.sup.20).sub.2,
NR.sup.20CON(R.sup.20).sub.2, OC(O)R.sup.20,
OC(O)N(R.sup.20).sub.2, SR.sup.20, S(O)R.sup.22, SO.sub.2R.sup.22,
SO.sub.2N(R.sup.20).sub.2, CN, or OR.sup.20;
[0128] R.sup.20 is selected from the group consisting of H,
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, heterocyclyl, aryl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or
heteroaryl amide, CN, O--C.sub.1-6 alkyl, CF.sub.3, aryl, and
heteroaryl; and
[0129] R.sup.22 is a member selected from the group consisting of
C.sub.1-15 alkyl, C.sub.2-15 alkenyl, C.sub.2-15 alkynyl,
heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl,
alkynyl, heterocyclyl, aryl, and heteroaryl substituents are
optionally substituted with from 1 to 3 substituents independently
selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or
heteroaryl amide, CN, O--C.sub.1-6 alkyl, CF.sub.3, and heteroaryl
wherein, when R.sup.1.dbd.CH.sub.2OH, R.sup.3 is H, R.sup.4 is H,
the pyrazole ring is attached through C.sup.4, and R.sup.2 is not
H.
[0130] When the compound is selected has one of the following
formulas: 3
[0131] then it is preferred that R.sup.1 is --CH.sub.2OH; R.sup.2
is selected from the group consisting of hydrogen, C.sub.1-8 alkyl
wherein the alkyl is optionally substituted with one substituent
independently selected from the group consisting of aryl, CF.sub.3,
CN, and wherein each optional aryl substituent is optionally
substituted with halo, alkyl, CF.sub.3 or CN; and R.sup.3 and
R.sup.4 are each independently selected from the group consisting
of hydrogen, methyl and more preferably, R.sup.3 and R.sup.4 are
each hydrogen.
[0132] When the compound of this invention has the following
formulas: 4
[0133] then it is preferred that R.sup.1 is --CH.sub.2OH; R.sup.2
is selected from the group consisting of hydrogen, and C.sub.1-6
alkyl optionally substituted by phenyl. More preferably, R.sup.2 is
selected from benzyl and pentyl; R.sup.3 is selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, aryl, wherein the alkyl,
and aryl substituents are optionally substituted with from 1 to 2
substituents independently selected from the group consisting of
halo, aryl, CF.sub.3, CN, and wherein each optional aryl
substituent is optionally substituted with halo, alkyl, CF.sub.3 or
CN; and R.sup.4 is selected from the group consisting of hydrogen
and C.sub.1-6 alkyl, and more preferably, R.sup.4 is selected from
hydrogen and methyl.
[0134] A more specific class of compounds is selected from the
group consisting of (4S,2R,3R,
5R)-2-{6-amino-2-[1-benzylpyrazol-4-yl]purin-9-y-
l}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-[6-amino-2-(1-pentyl-
pyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-[6-amino-2-(1-methylpyrazol-4-yl)purin-9-yl]-5-(hydroxyme-
thyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(methylethyl)pyrazol--
4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(3-phenylpropyl)pyrazol-4-yl]purin-9-yl}-5--
(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(4-t-butylb-
enzyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-(6-amino-2-pyrazol-4-ylpurin-9-yl)-5-(hydroxymethyl)oxola-
ne-3,4-diol, (4S,2R,3R,
5R)-2-{6-amino-2-[1-pent-4-enylpyrazol-4-yl]purin--
9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-dec-
ylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(cyclohexylmethyl)pyrazol-4-yl]purin-9-yl}--
5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(2-phenyl-
ethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(3-cyclohexylpropyl)pyrazol-4-yl]purin-9-yl-
}-5-(hydroxymethyl)oxolane-3,4-diol,
(4S,2R,3R,5R)-2-{6-amino-2-[1-(2-cycl-
ohexylethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,
and combinations thereof.
[0135] A very useful and potent and selective agonists for the
A.sub.2A adenosine receptor is CVT-3146 or
(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(h-
ydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxam-
ide which has the formula: 5
[0136] Another preferred compound that is useful as a selective
A.sub.2A-adenosine receptor agonist with a short duration of action
is a compound of the formula: 6
[0137] CVT-3033 is particularly useful as an adjuvant in
cardiological imaging.
[0138] The first and second classes of compounds identified above
are described in more detail in U.S. Pat. Nos. 6,403,567 and
6,214,807, the specification of each of which is incorporated
herein by reference.
[0139] The following definitions apply to terms as used herein.
[0140] "Halo" or "Halogen"--alone or in combination means all
halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo
(I).
[0141] "Hydroxyl" refers to the group --OH.
[0142] "Thiol" or "mercapto" refers to the group --SH.
[0143] "Alkyl"--alone or in combination means an alkane-derived
radical containing from 1 to 20, preferably 1 to 15, carbon atoms
(unless specifically defined). It is a straight chain alkyl,
branched alkyl or cycloalkyl. Preferably, straight or branched
alkyl groups containing from 1-15, more preferably 1 to 8, even
more preferably 1-6, yet more preferably 1-4 and most preferably
1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl,
t-butyl and the like. The term "lower alkyl" is used herein to
describe the straight chain alkyl groups described immediately
above. Preferably, cycloalkyl groups are monocyclic, bicyclic or
tricyclic ring systems of 3-8, more preferably 3-6, ring members
per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl
and the like. Alkyl also includes a straight chain or branched
alkyl group that contains or is interrupted by a cycloalkyl
portion. The straight chain or branched alkyl group is attached at
any available point to produce a stable compound. Examples of this
include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or
2-methyl-cyclopropylpentyl. A substituted alkyl is a straight chain
alkyl, branched alkyl, or cycloalkyl group defined previously,
independently substituted with 1 to 3 groups or substituents of
halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl,
acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or
di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea
optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl
groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with
alkyl, aryl or heteroaryl groups, alkylsulfonylamino,
arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino,
arylcarbonylamino, heteroarylcarbonylamino, or the like.
[0144] "Alkenyl"--alone or in combination means a straight,
branched, or cyclic hydrocarbon containing 2-20, preferably 2-17,
more preferably 2-10, even more preferably 2-8, most preferably
2-4, carbon atoms and at least one, preferably 1-3, more preferably
1-2, most preferably one, carbon to carbon double bond. In the case
of a cycloalkyl group, conjugation of more than one carbon to
carbon double bond is not such as to confer aromaticity to the
ring. Carbon to carbon double bonds may be either contained within
a cycloalkyl portion, with the exception of cyclopropyl, or within
a straight chain or branched portion. Examples of alkenyl groups
include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl,
cyclohexenylalkyl and the like. A substituted alkenyl is the
straight chain alkenyl, branched alkenyl or cycloalkenyl group
defined previously, independently substituted with 1 to 3 groups or
substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl,
alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally
mono- or di-substituted with alkyl, aryl or heteroaryl groups,
amidino, urea optionally substituted with alkyl, aryl, heteroaryl
or heterocyclyl groups, aminosulfonyl optionally N-mono- or
N,N-di-substituted with alkyl, aryl or heteroaryl groups,
alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,
alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino,
carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or
the like attached at any available point to produce a stable
compound.
[0145] "Alkynyl"--alone or in combination means a straight or
branched hydrocarbon containing 2-20, preferably 2-17, more
preferably 2-10, even more preferably 2-8, most preferably 2-4,
carbon atoms containing at least one, preferably one, carbon to
carbon triple bond. Examples of alkynyl groups include ethynyl,
propynyl, butynyl and the like. A substituted alkynyl refers to the
straight chain alkynyl or branched alkenyl defined previously,
independently substituted with 1 to 3 groups or substituents of
halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl,
acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or
di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea
optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl
groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with
alkyl, aryl or heteroaryl groups, alkylsulfonylamino,
arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino,
arylcarbonylamino, heteroarylcarbonylamino, or the like attached at
any available point to produce a stable compound.
[0146] "Alkyl alkenyl" refers to a group --R--CR'.dbd.CR'"R"",
where R is lower alkyl, or substituted lower alkyl, R', R'", R""
may independently be hydrogen, halogen, lower alkyl, substituted
lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted
hetaryl as defined below.
[0147] "Alkyl alkynyl" refers to a groups --RC.quadrature.CR' where
R is lower alkyl or substituted lower alkyl, R' is hydrogen, lower
alkyl, substituted lower alkyl, acyl, aryl, substituted aryl,
hetaryl, or substituted hetaryl as defined below.
[0148] "Alkoxy" denotes the group --OR, where R is lower alkyl,
substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl,
substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl,
substituted cycloalkyl, cycloheteroalkyl, or substituted
cycloheteroalkyl as defined.
[0149] "Alkylthio" denotes the group --SR, --S(O).sub.n=1-2--R,
where R is lower alkyl, substituted lower alkyl, aryl, substituted
aryl, aralkyl or substituted aralkyl as defined herein.
[0150] "Acyl" denotes groups --C(O)R, where R is hydrogen, lower
alkyl substituted lower alkyl, aryl, substituted aryl and the like
as defined herein.
[0151] "Aryloxy" denotes groups --OAr, where Ar is an aryl,
substituted aryl, heteroaryl, or substituted heteroaryl group as
defined herein.
[0152] "Amino" denotes the group NRR', where R and R' may
independently by hydrogen, lower alkyl, substituted lower alkyl,
aryl, substituted aryl, hetaryl, or substituted hetaryl as defined
herein or acyl.
[0153] "Amido" denotes the group --C(O)NRR', where R and R' may
independently by hydrogen, lower alkyl, substituted lower alkyl,
aryl, substituted aryl, hetaryl, substituted hetaryl as defined
herein.
[0154] "Carboxyl" denotes the group --C(O)OR, where R is hydrogen,
lower alkyl, substituted lower alkyl, aryl, substituted aryl,
hetaryl, and substituted hetaryl as defined herein.
[0155] "Aryl"--alone or in combination means phenyl or naphthyl
optionally carbocyclic fused with a cycloalkyl of preferably 5-7,
more preferably 5-6, ring members and/or optionally substituted
with 1 to 3 groups or substituents of halo, hydroxy, alkoxy,
alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy,
heteroaryloxy, amino optionally mono- or di-substituted with alkyl,
aryl or heteroaryl groups, amidino, urea optionally substituted
with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl
optionally N-mono- or N,N-di-substituted with alkyl, aryl or
heteroaryl groups, alkylsulfonylamino, arylsulfonylamino,
heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino,
heteroarylcarbonylamino, or the like.
[0156] "Substituted aryl" refers to aryl optionally substituted
with one or more functional groups, e.g., halogen, lower alkyl,
lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl,
hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl,
nitro, cyano, thiol, sulfamido and the like.
[0157] "Heterocycle" refers to a saturated, unsaturated, or
aromatic carbocyclic group having a single ring (e.g., morpholino,
pyridyl or furyl) or multiple condensed rings (e.g., naphthpyridyl,
quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having
at least one hetero atom, such as N, O or S, within the ring, which
can optionally be unsubstituted or substituted with, e.g., halogen,
lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido,
carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl,
substituted hetaryl, nitro, cyano, thiol, sulfamido and the
like.
[0158] "Heteroaryl"--alone or in combination means a monocyclic
aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic
aromatic group having 8 to 10 atoms, containing one or more,
preferably 1-4, more preferably 1-3, even more preferably 1-2,
heteroatoms independently selected from the group O, S, and N, and
optionally substituted with 1 to 3 groups or substituents of halo,
hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy,
aryloxy, heteroaryloxy, amino optionally mono- or di-substituted
with alkyl, aryl or heteroaryl groups, amidino, urea optionally
substituted with alkyl, aryl, heteroaryl or heterocyclyl groups,
aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl,
aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino,
heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino,
heteroarylcarbonylamino, or the like. Heteroaryl is also intended
to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide
of a tertiary ring nitrogen. A carbon or nitrogen atom is the point
of attachment of the heteroaryl ring structure such that a stable
aromatic ring is retained. Examples of heteroaryl groups are
pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, indolyl,
quinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl,
isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl,
triazinyl, furanyl, benzofuryl, indolyl and the like. A substituted
heteroaryl contains a substituent attached at an available carbon
or nitrogen to produce a stable compound.
[0159] "Heterocyclyl"--alone or in combination means a non-aromatic
cycloalkyl group having from 5 to 10 atoms in which from 1 to 3
carbon atoms in the ring are replaced by heteroatoms of O, S or N,
and are optionally benzo fused or fused heteroaryl of 5-6 ring
members and/or are optionally substituted as in the case of
cycloalkyl. Heterocycyl is also intended to include oxidized S or
N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring
nitrogen. The point of attachment is at a carbon or nitrogen atom.
Examples of heterocyclyl groups are tetrahydrofuranyl,
dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl,
dihydrobenzofuryl, dihydroindolyl, and the like. A substituted
hetercyclyl contains a substituent nitrogen attached at an
available carbon or nitrogen to produce a stable compound.
[0160] "Substituted heteroaryl" refers to a heterocycle optionally
mono or poly substituted with one or more functional groups, e.g.,
halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino,
amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted
heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol,
sulfamido and the like.
[0161] "Aralkyl" refers to the group --R--Ar where Ar is an aryl
group and R is lower alkyl or substituted lower alkyl group. Aryl
groups can optionally be unsubstituted or substituted with, e.g.,
halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido,
carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted
heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol,
sulfamido and the like.
[0162] "Heteroalkyl" refers to the group --R-Het where Het is a
heterocycle group and R is a lower alkyl group. Heteroalkyl groups
can optionally be unsubstituted or substituted with e.g., halogen,
lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido,
carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle,
hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and
the like.
[0163] "Heteroarylalkyl" refers to the group --R-HetAr where HetAr
is an heteroaryl group and R lower alkyl or substituted lower
alkyl. Heteroarylalkyl groups can optionally be unsubstituted or
substituted with, e.g., halogen, lower alkyl, substituted lower
alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle,
substituted heterocycle, hetaryl, substituted hetaryl, nitro,
cyano, thiol, sulfamido and the like.
[0164] "Cycloalkyl" refers to a divalent cyclic or polycyclic alkyl
group containing 3 to 15 carbon atoms.
[0165] "Substituted cycloalkyl" refers to a cycloalkyl group
comprising one or more substituents with, e.g., halogen, lower
alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl,
aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted
hetaryl, nitro, cyano, thiol, sulfamido and the like.
[0166] "Cycloheteroalkyl" refers to a cycloalkyl group wherein one
or more of the ring carbon atoms is replaced with a heteroatom
(e.g., N, O, S or P).
[0167] Substituted cycloheteroalkyl" refers to a cycloheteroalkyl
group as herein defined which contains one or more substituents,
such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene,
amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle,
substituted heterocycle, hetaryl, substituted hetaryl, nitro,
cyano, thiol, sulfamido and the like.
[0168] "Alkyl cycloalkyl" denotes the group --R-cycloalkyl where
cycloalkyl is a cycloalkyl group and R is a lower alkyl or
substituted lower alkyl. Cycloalkyl groups can optionally be
unsubstituted or substituted with e.g. halogen, lower alkyl, lower
alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl,
aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl,
substituted hetaryl, nitro, cyano, thiol, sulfamido and the
like.
[0169] "Alkyl cycloheteroalkyl" denotes the group
--R-cycloheteroalkyl where R is a lower alkyl or substituted lower
alkyl. Cycloheteroalkyl groups can optionally be unsubstituted or
substituted with e.g. halogen, lower alkyl, lower alkoxy,
alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl,
aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted
hetaryl, nitro, cyano, thiol, sulfamido and the like.
[0170] The first class of compounds identified above can be
prepared as outlined in Schemes 1-4.
[0171] Compounds having the general formula IV can be prepared as
shown in Scheme 1. 7
[0172] Compound I can be prepared by reacting compound 1 with
appropriately substituted 1,3-dicarbonyl in a mixture of AcOH and
MeOH at 80.degree. C. (Holzer et al., J. Heterocycl. Chem. (1993)
30, 865). Compound II, which can be obtained by reacting compound I
with 2,2-dimethoxypropane in the presence of an acid, can be
oxidized to the carboxylic acid III, based on structurally similar
compounds using potassium permanganate or pyridinium chlorochromate
(M. Hudlicky, (1990) Oxidations in Organic Chemistry, ACS
Monographs, American Chemical Society, Washington D.C.). Reaction
of a primary or secondary amine having the formula
HNR.sup.6R.sup.7, and compound III using DCC (M. Fujino et al.,
Chem. Pharm. Bull. (1974), 22, 1857), PyBOP (J. Martinez et al., J.
Med. Chem. (1988) 28, 1874) or PyBrop (J. Caste et al. Tetrahedron,
(1991), 32, 1967) coupling conditions can afford compound IV. 8
[0173] Compound V can be prepared as shown in Scheme 2. The Tri
TBDMS derivative 4 can be obtained by treating compound 2 with
TBDMSCl and imidazole in DMF followed by hydrolysis of the ethyl
ester using NaOH. Reaction of a primary or secondary amine with the
formula HNR.sup.6R.sup.7, and compound 4 using DCC (M. Fujino et
al., Chem. Pharm. Bull. (1974), 22, 1857), PyBOP (J. Martinez et
al., J. Med. Chem. (1988) 28, 1874) or PyBrop (J. Caste et al.
Tetrahedron, (1991), 32, 1967) coupling conditions can afford
compound V. 910
[0174] A specific synthesis of Compound 11 is illustrated in Scheme
3. Commercially available guanosine 5 was converted to the
triacetate 6 as previously described (M. J. Robins and B. Uznanski,
Can. J. Chem. (1981), 59, 2601-2607). Compound 7, prepared by
following the literature procedure of Cerster et al. (J. F.
Cerster, A. F. Lewis, and R. K. Robins, Org. Synthesis, 242-243),
was converted to compound 9 in two steps as previously described
(V. Nair et al., J. Org. Chem., (1988), 53, 3051-3057). Compound 1
was obtained by reacting hydrazine hydrate with compound 9 in
ethanol at 80.degree. C. Condensation of compound 1 with
ethoxycarbonylmalondialdehyde in a mixture of AcOH and MeOH at
80.degree. C. produced compound 10. Heating compound 10 in excess
methylamine afforded compound 11. 11
[0175] The synthesis of 1,3-dialdehyde VII is described in Scheme
4. Reaction of 3,3-diethoxypropionate or 3,3-diethoxypropionitrile
or 1,1-diethoxy-2-nitroethane VI (R.sub.3.dbd.CO.sub.2R, CN or
NO.sub.2) with ethyl or methyl formate in the presence of NaH can
afford the dialdehyde VII (Y. Yamamoto et al., J. Org. Chem. (1989)
54, 4734).
[0176] The second class of compound described above may be prepared
by as outlined in schemes 1-5. Compounds having the general formula
II: 12
[0177] were prepared by the palladium mediated coupling of compound
1 with halo-pyrazoles represented by the formula VIII (scheme 4) in
the presence or absence of copper salts (K. Kato et. al. J. Org.
Chem. 1997, 62, 6833-6841; Palladium Reagents and
Catalysts-Innovations in Organic Synthesis, Tsuji, John Wiley and
Sons, 1995) followed by de-protection with either TBAF or NH.sub.4F
(Markiewicz et. al Tetrahedron Lett. (1988), 29, 1561). The
preparation of compound 1 has been previously described (K. Kato
et. al. J. Org. Chem. 1997, 62,6833-6841) and is outlined in scheme
5.
[0178] Compounds with general formula VI can be prepared as shown
in Scheme 2. Compound III, which can be obtained by reacting II
with 2,2-dimethoxypropane in presence of an 13
[0179] acid, can be oxidized to the carboxylic acid IV, based on
structurally similar compounds, using potassium permanganate or
pyridinium chlorochromate etc. (Jones et. al., J. Am. Chem. Soc.
(1949), 71, 3994; Hudlicky, Oxidations in organic chemistry,
American Chemical Society, Washington D.C., 1990) to compound IV.
Reaction of primary or secondary amine of the formula
NHR.sup.5R.sup.6, and compound IV using DCC (Fujino et. al., Chem.
Pharm. Bull. (1974), 22, 1857), PyBOP (J. Martinez et. al., J. Med.
Chem. (1988), 28, 1967) or PyBrop (J. Caste et. al. Tetrahedron,
(1991), 32, 1967) coupling conditions can afford compound V.
Deprotection of compound V can be performed by heating with 80% aq.
acetic acid (T. W. Green and P. G. M. Wuts, (1991), Protective
Groups in Organic Synthesis, A, Wiley-Interscience publication) or
with anhydrous HCl (4N) to obtain compound of the general formula
VI.
[0180] Alternatively, compounds with the general formula II can
also be prepared by Suzuki type coupling as shown in scheme 3.
14
[0181] 2-Iodoadenosine 6 can be prepared in four steps from
guanosine 2 following literature procedures (M. J. Robins et. al.
Can. J. Chem. (1981), 59, 2601-2607; J. F. Cerster et. al. Org.
Synthesis, --242-243; V. Nair at. al., J. Org. Chem., (1988), 53,
3051-3057). Palladium mediated Suzuki coupling of 6 with
appropriately substituted pyrazole-boronic acids XVII in presence
of a base can provide final compounds with general formula II (A.
Suzuki, Acc. Chem. Res) (1982), 15, 178). If necessary, 2', 3', 5'
hydroxyls on 6 can be protected as TBDMS ethers prior to Suzuki
coupling.
[0182] Compounds with the general formula VIII can be either
commercially available or prepared following the steps shown in
scheme 4. 15
[0183] Condensation of 1,3-diketo compounds of the formula IX with
hydrazine in an appropriate solvent can give pyrazoles with the
general formula X (R. H. Wiley et. al. Org. Synthsis, Coll. Vol IV
(1963), 351. These pyrazoles can be N-alkylated with various alkyl
halides to give compounds of the formula XI which on iodination
give 4-iodo derivatives with the general formula VIII (R. Huttel
et. al. Justus Liebigs Ann. Chem. (1955), 593, 200).
[0184] 5-iodopyrazoles with the general formula XV can be prepared
following the steps outlined in the scheme 5. 16
[0185] Condensation of 1,3-diketo compounds of the formula XII with
hydrazine in an appropriate solvent can give pyrazoles with the
general formula XIII. These pyrazoles can be N-alkylated with
various alkyl halides to give compounds of the formula XIV.
Abstraction of 5-H with a strong base followed by quenching with
iodine can provide 5-iodo derivatives with general formula XV (F.
Effenberger et. al. J. Org. Chem. (1984), 49, 4687).
[0186] 4- or 5-iodopyrazoles can be transformed into corresponding
boronic acids as shown in the scheme 6. Transmetallation with
n-buLi followed by treatment with trimethylborate can 17
[0187] give compounds with the general formula XVI which on
hydrolysis can provide boronic acids with the general formula XVII
(F. C. Fischer et. al. RECUEIL (1965), 84, 439).
[0188] 2-Stannyladenosine 1 was prepared in three steps from the
commercially available 6-chloropurine riboside following literature
procedure (K. Kato et. al., J. Org. Chem. (1997), 62, 6833-6841).
Tri TBDMS derivative was obtained by treating 8 with TBDMSCl and
imidazole in DMF. Lithiation with LTMP followed by quenching with
tri n-butyltin chloride gave exclusively 2-stannyl derivative 10.
Ammonolysis in 2-propanol gave 2-stannyladenosine 1. Stille
coupling of 1 with 1-benzyl-4-iodopyrazole in presence of
Pd(PPh3).sub.4 and CuI resulted in 11 (K. Kato et. al., J. Org.
Chem. (1997), 62, 6833-6841). Deprotection of silyl groups on 2',
3' and 5' 1819
[0189] hydroxyls with 0.5 M ammonium fluoride in methanol gave 12
in good yield (Scheme 7). The methods used to prepare the compounds
of this invention are not limited to those described above.
Additional methods can be found in the following sources and are
included by reference (J. March, Advanced Organic Chemistry;
Reaction Mechanisms and Studies (1992), A Wiley Interscience
Publications; and J. Tsuji, Palladium reagents and
catalysts-Innovations in organic synthesis, John Wiley and Sons,
1995).
[0190] If the final compound of this invention contains a basic
group, an acid addition salt maybe prepared. Acid addition salts of
the compounds are prepared in a standard manner in a suitable
solvent from the parent compound and an excess of acid, such as
hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic,
succinic, or methane sulfonic. The hydrochloric salt form is
especially useful. If the final compound contains an acidic group,
cationic salts may be prepared. Typically the parent compound is
treated with an excess of an alkaline reagent, such as hydroxide,
carbonate or alkoxide, containing the appropriate cation. Cations
such as Na.sup.+, K.sup.+, Ca.sup.+2 and NH.sub.4.sup.+ are
examples of cations present in pharmaceutically acceptable salts.
Certain of the compounds form inner salts or zwittcrions which may
also be acceptable.
EXAMPLES
[0191] Three different aqueous pharmaceutical CVT-3146 formulations
were used in the Examples below.
[0192] Examples 1-7 employed aqueous pharmaceutical compositions
(a) and (b) below. Pharmaceutical compositions (a) and (b) were
aseptically filled into 10 mL type I glass vials.
[0193] (a) An aqueous pharmaceutical composition consisting of 200
micrograms/mL of CVT-3146 in 0.5 (w:v) methylboronic acid buffered
with sodium bicarbonate to a pH of 9.3.
[0194] (b) An aqueous pharmaceutical composition including 200
micrograms/mL of CVT-3146, 0.1% (w:v) methylboronic acid, 50 mM
sodium bicarbonate buffer adjusted to pH 9.3 with the addition of
0.55% (w:v) NaCl to make an isotonic pharmaceutical
composition.
[0195] Example 8 employed a pharmaceutical composition consisting
of an aqueous composition of 100 micrograms/mL CVT-3146 in 15%
(w:v) propylene glycol and 100 mM phosphate buffer at pH 7 with
0.1% EDTA. The formulation was stored in type I glass vials at 5 mL
per vial.
Example 1
[0196] BACKGROUND: CVT-3146 (CVT), with an initial half-life of 3
minutes with a rapid onset and offset of action, is >100-fold
more potent than adenosine (Ado) in increasing coronary blood flow
velocity (CBFv) in awake dogs. The purpose of this open label study
was to determine the magnitude and duration of effect of CVT-3146
(10-500 .mu.g) on CBFv in humans.
[0197] METHODS: Patients undergoing a clinically indicated coronary
catheterization with no more than a 70% stenosis in any coronary
artery and no more than a 50% stenosis of the study vessel had CBFv
determined by Doppler flow wire. Study subject were selected after
measuring baseline and peak CBFv after an intracoronary (IC)
injection of 18 .mu.g of Ado. Twenty-three patients, who were
identified as meeting the study criteria of having a peak to
baseline CBFv ratio of .gtoreq.2.5 in response to Adenosine,
received a rapid (.ltoreq.10 sec) peripheral IV bolus of CVT-3146;
Doppler signals were stable and interpretable over the time-course
of the increase in CBFv in 17 patients.
[0198] RESULTS CVT-3146 caused a rapid increase in CBFv that was
near peak by 30 to 40 seconds post onset of bolus. CVT-3146 at
doses of 100 .mu.g (n=3), 300 .mu.g (n=4), and 500 .mu.g (n=2)
induced a peak to baseline ratio of 3.2.+-.0.6 (mean.+-.SD),
similar to that obtained by IC Ado (3.2.+-.0.5). The duration of
CBFv augmentation (.gtoreq.2-fold increase in CBFv) was dose
dependent; at 300 .mu.g the duration was 4.0.+-.4.9 minutes and at
500 .mu.g was 6.9.+-.7.6 minutes. At 500 .mu.g (n=3) the maximal
increase in heart rate (HR) was 18.7.+-.4.0 and the maximal
decrease in systolic blood pressure (BP) was 8.7.+-.7.6. Adverse
events (AEs) were infrequent and included nausea, flushing, and
headache; these were mild and self-limited. No AEs were noted in
the 3 patients receiving the 500 .mu.g dose.
[0199] CONCLUSION: In humans peak CBFv following CVT-3146 (IV
bolus) is comparable to CBFv following IC Ado without major changes
in either HR or BP. This agent's magnitude and duration of effect,
adverse event profile and bolus administration make CVT-3146 a
useful pharmacological stress agent for myocardial perfusion
imaging.
Example 2
[0200] This example is a study performed to determine the range of
dosages over which the selective A.sub.2A receptor agonist,
CVT-3146 can be administered and be effective as a coronary
vasodilator.
[0201] The study included patients undergoing a clinically
indicated coronary catheterization with no more than a 70% stenosis
in any coronary artery and no more than a 50% stenosis of the study
vessel had CBFv determined by Doppler flow wire. Study subject were
selected after measuring baseline and peak CBFv after an
intracoronary (IC) injection of 18 .mu.g of Ado. 36 subjects were
identified as meeting the study criteria of having a peak to
baseline CBFv ration of .gtoreq.2.5 in response to Adenosine,
CVT-3146 was administered to the study subjects by IV bolus in less
that 10 seconds in amounts ranging from 10 .mu.g to 500 .mu.g.
[0202] The effectiveness of both compounds was measured by
monitoring coronary flow velocity. Other coronary parameters that
were monitored included heart rate and blood pressure. These
parameters were measured in order to evaluate the time to peak dose
response, the magnitude of the dose response and the duration of
the dose response. Adverse events were also monitored. Coronary
blood flow velocity was measured at the left anterior descending
coronary artery (LAD) or left circumflex coronary artery (LCx). The
velocity measurements were taken by following standard heart
catheterization techniques and inserting a 0.014 inch
Doppler-tipped Flowire into the LAD or LCx vessel and thereafter
monitoring blood flow velocity. In addition, hemodynamic and
electrocardiographic measurements were recorded continuously.
[0203] Overall, 36 human subjects (n=36) were evaluated. Of the 36,
18 were female and 18 were male. Their mean age was 53.4 and they
ranged from 24-72 years in age. Of the 36 subjects evaluated, the
LAD vessel of 31 subjects was monitored, and the LCx vessel of 5
subjects was monitored. The following doses (.mu.g) of CVT-3146
were given to the subjects in a single iv bolus: 10 (n=4); 30
(n=6); 100 (n=4); 300 (n=7); 400 (n=9); 500 (n=6).
[0204] The study results are reported in FIGS. 1-6. The plot of
FIG. 1 shows that CVT-3146 increases peak flow velocity in amounts
as low as 10 .mu.g and reaches plateau peak velocity upon
administration of less than about 100 .mu.g of CVT-3146. Other test
results and conclusions include:
[0205] The peak flow was reached by about 30 seconds with all
doses;
[0206] At does above about 100 .mu.g, peak effects were equivalent
to 18 .mu.g adenosine administered IC;
[0207] CVT-3146 was generally well tolerated with adverse events
being reported in The table attached as FIG. 7;
[0208] At 400 .mu.g:
[0209] Coronary blood flow velocity .gtoreq.2.5-fold above baseline
was maintained for 2.8 minutes.
[0210] Maximum increase in heart rate (18.+-.8 bpm) occurs about 1
minute after dosing.
[0211] Maximum decrease in systolic BP (20.+-.8 mmHg) occurs about
1 minute after dosing.
[0212] Maximum decrease in diastolic BP (10.+-.5 mmHg) occurs about
1 minute after dosing.
Example 3
[0213] This Example is a study performed to evaluate (1) the
maximum tolerated dose of CVT-3146 and (2) the pharmacokinetic
profile of CVT-3146 in healthy volunteers, after a single IV bolus
dose.
[0214] Methods
[0215] The study was performed using thirty-six healthy,
non-smoking male subjects between the ages of 18 and 59 and within
15% of ideal body weight.
[0216] Study Design
[0217] The study was performed in phase 1, single center,
double-blind, randomized, placebo-controlled, crossover, ascending
dose study. Randomization was to CVT-3146 or placebo, in both
supine and standing positions.
[0218] CVT-3146 was administered as an IV bolus (20 seconds) in
ascending doses of 0.1, 0.3, 1.3, 10, 20 and 30 .mu.g/kg.
[0219] Subjects received either CVT-3146 of placebo on Day 1
supine, then crossover treatment on Day 2 supine. On Day 3,
subjects received CVT-3146 or placebo standing, then crossover
treatment on Day 4 standing.
[0220] Assessments
[0221] Patient safety was monitored by ECG, laboratory assessments,
and collection of vital signs and adverse events.
[0222] Pharmacokinetics:
[0223] Plasma samples were drawn during supine phase (Days 1 and 2)
at 0, 1, 2, 3, 4, 5, 7, 10, 15, 20, 30, 45 minutes after dosing and
at 1, 1.5, 2, 4, 6, 8, 12 and 24 hours after dosing. Urine was
collected for 24 hours for CVT-3146 excretion.
[0224] Pharmacodynamics:
[0225] The study evaluated the relationship of changes in heart
rate to dose in both standing and supine positions and plasma
concentration in the supine position. Some of the study results are
reported in FIGS. 8-14.
[0226] Results
[0227] Safety
[0228] In general, adverse events reflected the pharmacologic
effect of CVT-3146 and were related to vasodilation or an increase
in heart rate (HR). Overall, adverse events were short-lived and
mild to moderate in severity. There were no serious adverse events.
Three events were assessed as severe in intensity. (Table 1).
1TABLE 1 Adverse Events labeled as severe in intensity Number of
Subjects with AE 20 .mu.g/kg 30 .mu.g/kg Event Standing Supine No
subjects per group 4 4 Palpitation 0 2 Dizziness 1 0 Syncope 1
0
[0229] A three-compartment open model was fit to the data using
observed Tmax (1-4 minutes) as the duration of a zero-order
infusion. Reliable parameter estimates were obtained for dose of
1-30 .mu.g/kg. Parameters are summarized in the following (Table
2):
2TABLE 2 Mean (SD) CVT-3146 Pharmacokinetic Parameters Estimated
Using a Three - Compartment Model Dose (.mu.g/kg) 1 3 10 20 30
Total N 3 4 4 8 3 22 CL 737 668 841 743 1021 768 (mL/min) (106)
(167) (120) (123) (92.7) (168) Vc (L) 9.84 13.7 17.9 12.5 15.7 13.8
(4.12) (6.06) (6.11) (5.83) (4.59) (5.67) Vss (L) 69.0 90.0 101
75.2 89.6 75.5 (28.2) (29.6) (11.3) (10.6) (10.9) (24.4) .alpha.
Half-life 2.14 3.11 4.15 4.69 3.00 3.73 (min) (1.38) (2.14) (2.75)
(4.01) (1.05) (2.88) .beta. Half-life 8.93 17.2 50.2 32.6 14.0 27.2
(min) (4.10) (11.4) (52.1) (32.4) (4.98) (31.0) .lambda. Half-life
99.0 130 132 117 99.4 86.4 (min) (28.6) (23.1) (20.5) (36.0) (8.10)
(57.5) K21 (1/min) 0.246 0.203 0.187 0.387 0.0948 0.258 (0.255)
(0.272) (0.305) (0.615) (0.0443) (0.410) K31 (1/min) 0.01808 0.0152
0.0108 0.0141 0.0148 0.0143 (0.00548) (0.00490) (0.00592) (0.00728)
(0.000900) (0.00580) CL = clearance Vc = central volume of
distribution V.sub.ss = volume of distribution at steady state
K.sub.21 = the rate constant for transfer from first peripheral to
central compartment K.sub.31 = rate constant for transfer from
second peripheral to central compartment
[0230] Results
[0231] CVT-3146 was well-tolerated, with AE's mainly representing
its pharmacological effects as an adenosine A.sub.2A receptor
agonist.
[0232] Mean tolerable dose for CVT-3146 was 10 .mu.g/kg standing
and 20 .mu.g/kg supine.
[0233] CVT-3146 does not require weight-adjusted dosing.
[0234] There was no time lag between plasma concentration changes
and changes in heart rate.
[0235] The relationship between HR increase and dose or
concentration was adequately described with a sigmoidal Emax
model.
Example 4
[0236] CVT-3146 is a novel selective A.sub.2A adenosine receptor
agonist being developed as a pharmacologic stressor for
radionuclide myocardial perfusion imaging. Previously it has been
shown that CVT-3146 causes coronary vasodilation without
significantly affecting either total peripheral resistance or renal
blood flow in awake dogs. The goal of this study was to determine
the differential effects of CVT-3146 on blood flow velocity in
various vascular beds.
[0237] The effect of CVT-3146 was studied on the blood flow
velocity in left circumflex coronary artery (LCX), brain arterial
vasculature (BA), forelimb artery (FA) and pulmonary artery (PA) of
comparable diameter in the anesthetized dog. CVT3146 (1.0 .mu.g/kg)
was administered as an intravenous bolus, transiently enhanced
blood flow which was site specific. The effects of CVT-3146 were
quantified as the average peak blood flow velocity (APV) using
intravascular Doppler transducer tipped catheter. Heart rate (HR)
and systemic arterial blood pressure (BP) were also monitored.
[0238] APV increased 3.1.+-.0.2, 1.4.+-.0.1, 1.2.+-.0.1, and
1.1.+-.0.01 fold in the LCX, BA, FA and PA, respectively
manifesting a site-potency rank order of LCX>>BA>FA>PA
(FIG. 16). The effect of CVT-3146 on blood flow velocity was short
lasting; reaching a peak in less than 30 sec and dissipating in
less than ten minutes. Increased blood flow velocity was associated
with a small transient increase in HR (16 bpm) and decrease in BP
(12 mmHg). In conclusion, this study demonstrated that CVT-3146 is
a potent, short lasting vasodilator that is highly selective for
the coronary vasculature.
Example 5
[0239] The present study was carried out to determine whether
CVT-3146, a selective A.sub.2A adenosine receptor agonist, causes
sympathoexcitation.
[0240] CVT (0.31 .mu.g/kg-50 .mu.g/kg) was given as a rapid i.v.
bolus to awake rats and heart rate (HR) and blood pressure (BP)
were monitored. CVT-3146 caused an increase in BP and systolic
pressure (SP) at lower doses while at higher doses there was a
decrease in BP and SP. CVT-3146 caused a dose-dependent increase in
HR (FIG. 17). The increase in HR was evident at the lowest dose of
CVT at which there was no appreciable decrease in BP. ZM241385 (30
.mu.g/kg, N=5), an A.sub.2A receptor antagonist, attenuated the
decrease in BP (CVT-3146: 14.+-.3%, ZM: 1.+-.1%) and the increase
in HR (CVT: 27.+-.3%, ZM: 18.+-.3%) caused by CVT-3146.
Pretreatment with metoprolol (MET, 1 mg/kg, n=5), a beta-blocker,
attenuated the increase in HR (CVT: 27.+-.3%, MET: 15.+-.2%), but
had no effect on hypotension caused by CVT-3146. In the presence of
hexamethonium (HEX, 10 mg/kg, n=5), a ganglionic blocker, the
tachycardia was prevented (CVT: 27.+-.3%, HEX: -1.+-.2%), but BP
was further reduced (CVT: -11.+-.2%, HEX: -49.+-.5%). CVT-3146 (10
.mu.g/kg, n=6) also significantly (p<0.05) increased plasma
norepinephrine (control: 146.+-.11, CVT-3146 269.+-.22 ng/ml) and
epinephrine (control:25:f:5, CVT:100:f:20 ng/ml) levels. The
separation of HR and BP effects by dose, time and pharmacological
interventions provides evidence that tachycardia caused by CVT-3146
is independent of the decrease in BP, suggesting that CVT-3146, via
activation of A.sub.2A receptors may cause a direct stimulation of
the sympathetic nervous system.
Example 6
[0241] Pharmacologic stress SPECT myocardial perfusion imaging
(MPI) with adenosine (A) is a well-accepted technique, with
excellent diagnostic and prognostic value and proven safety.
However, side effects are common and AV nodal block and severe
flushing are poorly tolerated. Agents such as CVT-3146 selectively
act upon the A2A adenosine receptor and avoid stimulation of other
receptor subtypes which may prevent such adverse reactions.
[0242] To determine the ability of CVT-3146 to produce coronary
hyperemia and accurately detect CAD, 35 subjects (26 men, 9 women;
67.+-.10 years) underwent both A and CVT-3146 stress/rest MPI, with
10.0.+-.9.1 days between studies. Prior MI was noted in 12
patients, and many had prior revascularization [CABG (n=19), PCI
(n=22)]. CVT-3146 [400 mcg (n=18), 500 mcg (n=17)] was administered
as an IV bolus immediately followed by a saline flush, and then a
Tc-99m radiopharmaceutical [sestamibi (n=34), tetrofosmin (n=1)].
SPECT images were uniformly processed, intermixed with control
studies (normal and fixed-only defects), and interpreted by three
observers in a blinded fashion using a 17-segment model.
Quantitative analysis was also performed using 4D MSPECT. In
addition to three separate readings, a consensus interpretation was
performed and then a direct, same-screen comparison of A and
CVT-3146 images undertaken to determine relative differences, using
5 regions per study.
[0243] The summed scores following stress were similar, both with
visual (A=13.9.+-.1.5, CVT-3146=13.2.+-.1.3; p=n.s.) and
quantitative methods of analysis (A=13.7.+-.1.5,
CVT-3146=13.6.+-.1.6; p=n.s.). Similarly, comparisons between the
summed rest and summed difference scores were identical. The direct
comparison also revealed no differences in ischemia detection, with
a regional concordance for ischemia extent and severity of 86.3%
and 83.4%, respectively. No dose-dependent effect of CVT-3146 on
ischemia detection was noted. A conclusion of the study is that
CVT-3146, administered by a logistically simple bolus injection,
provides a similar ability to detect and quantify myocardial
ischemia with SPECT MPI as noted with an A infusion.
Example 7
[0244] CVT-3146 is a selective A2A adenosine receptor agonist that
produces coronary hyperemia and potentially less adverse effects
due to its limited stimulation of receptor subtypes not involved
with coronary vasodilation. This study evaluated the effectiveness
of CVT-3146 as a pharmacologic stress agent. 36 subjects (27 men, 9
women; 67.+-.10 years) were studied with two doses of CVT-3146 [400
mcg (n=18), 500 mcg (n=18)], administered as an IV bolus, as part
of a pharmacologic stress myocardial perfusion imaging
protocol.
[0245] Adverse effects (AE) occurred in 26 pts (72%), including
chest discomfort (33%), headache (25%), and abdominal pain (11%),
with a similar incidence for both doses. Flushing, dyspnea, and
dizziness were more frequent in the 500-mcg group (44%, 44%, and
28%, respectively) than in the 400-mcg group (17%, 17%, and 11%,
respectively). Most AEs were mild to moderate (96%) and resolved
within 15 min without treatment (91%). One serious AE occurred,
with exacerbation of a migraine headache, which required
hospitalization. ST and T wave abnormalities developed with
CVT-3146 in 7 and 5 pts, respectively. No 2nd or 3rd degree AV
block was noted and there were no serious arrhythmias. Peak
hemodynamic effects are shown in Table 3 and were noted at 4 min
for systolic blood pressure (BP), 8 min for diastolic BP, and
within 2 min for heart rate (HR). The effect on BP was minimal and
systolic BP did not fall below 90 mmHg with either dose. The mean
change in HR response was higher for the 500 mcg dose (44.2%) than
for 400 mcg (34.8%; p=n.s.). Thirty min after CVT-3146, BP changes
deviated <2% from baseline but HR remained above baseline by
8.6%.
[0246] The results of this study indicate that CVT-3146 is
well-tolerated and has acceptable hemodynamic effects. Minimal
differences were noted in BP and HR responses between the 400 mcg
and 500 mcg doses, but AEs were more frequently at the higher dose.
CVT-3146 appears safe and well-tolerated for bolus-mediated
pharmacologic stress perfusion imaging. Hemodynamic Changes
(mean.+-.S.D.)
3TABLE 3 Absolute Change Relative Change Heart Rate +21.9 .+-. 10.4
beats per min +36.7% + 21% Systolic BP -5.9 .+-. 10.7 mmHg -4.1%
.+-. 7.6% Diastolic BP -5.4 .+-. 7.2 mmHg -7.9% .+-. 10.5%
Example 8
[0247] In this study the vasodilator effects of CVT-3146 were
compared to those of ADO in different vascular beds in awake dogs.
Dogs were chronically instrumented for measurements of the blood
flow in coronary (CBF), mesenteric (MBF), hind limb (LBF), and
renal (RBF) vascular beds, and hemodynamics. Bolus injections (iv)
to CVT-3146 (0.1 to 2.5 .mu.g/kg) and ADO (10 to 250 .mu.g/kg)
caused significant increases in CBF (35.+-.6 to 205.+-.23% and
58.+-.13 to 163.+-.16%) and MBF (18.+-.4 to 88.+-.14% and 36.+-.8
to 84.+-.5%).
[0248] The results of the study demonstrate that CVT-3146 is a more
potent and longer lasting coronary vasodilator compared to ADO (the
duration for CBF above 2-fold of the baseline; CVT-3146 (2.5
.mu.g/kg): 130.+-.19 s; ADO (250 .mu.g/kg): 16.+-.3 s, P<0.5).
As shown in FIG. 18 (mean.+-.SE, n=6), CVT-3146 caused a smaller
increase in LBF than ADO. ADO caused a dose-dependent renal
vasoconstriction (RBF -46.+-.7 to -85.+-.4%), whereas CVT-3146 has
no or a little effect on RBF (-5.+-.2 to -11.+-.4%, P<0.05,
compared to ADO). In conclusion, CVT-3146 is a more selective and
potent coronary vasodilator than ADO. CVT-3146 has no the
significant effect on renal blood flow in awake dogs. These
features of CVT-3146 make it an ideal candidate for radionuclide
myocardial perfusion imaging.
[0249] The invention now having been fully described, it will be
apparent to one of ordinary skill in the art that many changes and
modifications can be made thereto without departing from the spirit
or scope of the invention.
* * * * *